$15.34
0[0.00%]
At close: Apr 23
$15.34
0[0.00%]
PreMarket: 4:00PM EDT
Y-mAbs Therapeutics
(NASDAQ:YMAB)Y-mAbs Therapeutics Stock (NASDAQ:YMAB), Analyst Ratings, Price Targets, Predictions
Y-mAbs Therapeutics Inc has a consensus price target of $17.25, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Canaccord Genuity, and BMO Capital on March 6, 2024, March 4, 2024, and March 4, 2024. With an average price target of $24.67 between HC Wainwright & Co., Canaccord Genuity, and BMO Capital, there's an implied 60.80% upside for Y-mAbs Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Canaccord Genuity
BMO Capital
JP Morgan
Morgan Stanley
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Y-mAbs Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/06/2024 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 43.42% | HC Wainwright & Co. | Robert Burns | — | Maintains | Buy | Get Alert |
| 03/04/2024 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 69.49% | Canaccord Genuity | Bill Maughan | $22 → $26 | Maintains | Buy | Get Alert |
| 03/04/2024 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 69.49% | BMO Capital | Etzer Darout | $16 → $26 | Maintains | Outperform | Get Alert |
| 02/20/2024 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 36.9% | HC Wainwright & Co. | Robert Burns | $11 → $21 | Maintains | Buy | Get Alert |
| 11/15/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -28.29% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 08/22/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -54.37% | JP Morgan | Tessa Romero | $8 → $7 | Maintains | Underweight | Get Alert |
| 08/14/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -67.41% | Morgan Stanley | Michael Ulz | $7 → $5 | Maintains | Underweight | Get Alert |
| 08/14/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -28.29% | HC Wainwright & Co. | Robert Burns | → $11 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 43.42% | Canaccord Genuity | William Plovanic | $21 → $22 | Maintains | Buy | Get Alert |
| 06/07/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 36.9% | Canaccord Genuity | William Plovanic | → $21 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -21.77% | B of A Securities | Alec Stranahan | $6 → $12 | Maintains | Neutral | Get Alert |
| 05/10/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -54.37% | Morgan Stanley | Michael Ulz | $4 → $7 | Maintains | Underweight | Get Alert |
| 05/10/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -15.25% | Wedbush | David Nierengarten | $5 → $13 | Upgrade | Neutral → Outperform | Get Alert |
| 05/09/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 36.9% | Canaccord Genuity | William Plovanic | $18 → $21 | Maintains | Buy | Get Alert |
| 04/04/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -28.29% | HC Wainwright & Co. | Robert Burns | $19 → $11 | Maintains | Buy | Get Alert |
| 04/03/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | — | Guggenheim | Etzer Darout | — | Downgrade | Buy → Neutral | Get Alert |
| 04/01/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -60.89% | B of A Securities | Alec Stranahan | → $6 | Maintains | Neutral | Get Alert |
| 03/31/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | 17.34% | Canaccord Genuity | William Maughan | $20 → $18 | Maintains | Buy | Get Alert |
| 01/30/2023 | YMAB | Buy Now | Y-mAbs Therapeutics | $15.34 | -15.25% | BMO Capital | Etzer Darout | $12 → $13 | Maintains | Outperform | Get Alert |
FAQ
What is the target price for Y-mAbs Therapeutics (YMAB)?
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by HC Wainwright & Co. on March 6, 2024. The analyst firm set a price target for $22.00 expecting YMAB to rise to within 12 months (a possible 43.42% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Y-mAbs Therapeutics (YMAB)?
The latest analyst rating for Y-mAbs Therapeutics (NASDAQ: YMAB) was provided by HC Wainwright & Co., and Y-mAbs Therapeutics maintained their buy rating.
When was the last upgrade for Y-mAbs Therapeutics (YMAB)?
The last upgrade for Y-mAbs Therapeutics Inc happened on May 10, 2023 when Wedbush raised their price target to $13. Wedbush previously had a neutral for Y-mAbs Therapeutics Inc.
When was the last downgrade for Y-mAbs Therapeutics (YMAB)?
The last downgrade for Y-mAbs Therapeutics Inc happened on April 3, 2023 when Guggenheim changed their price target from N/A to N/A for Y-mAbs Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Y-mAbs Therapeutics (YMAB)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on March 6, 2024 so you should expect the next rating to be made available sometime around March 6, 2025.
Is the Analyst Rating Y-mAbs Therapeutics (YMAB) correct?
While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a maintained with a price target of $21.00 to $22.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $15.34, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.